Enhancement and / or representation of a-sodium channel subunits regulated by type 1 (SCN1A) voltage in biological systems Pharmaceutical ingredients, including one or more compounds that increase SCN1A performance and are used to treat children with severe myopic epilepsy (emgi) or Dravet syndrome.
COLLARD, JOSEPH,KHORKOVA SHERMAN, OLGA,HSIAO, JANE H.
申请号：
CL2014000550
公开号：
CL2014000550A1
申请日:
2014.03.06
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.MÉTODO PARA INCREMENTAR LA FUNCIÓN Y/O EXPRESIÓN DE UN POLINUCLEÓTIDO O PROTEÍNA DE SUBUNIDAD ALFA DE CANAL DE SODIO REGULADO POR VOLTAJE TIPO 1 (SCN1A) EN SISTEMAS BIOLÓGICOS, COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNO O MÁS COMPUESTOS QUE AUMENTAN LA EXPRESIÓN DE SCN1A Y SU USO PARA EL TRATAMIENTO DE LA EPILEPSIA MIOCLÓNICA GRAVE DE LA INFANCIA (EMGI) O SÍNDROME DE DRAVET.
